GRIN2B — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL103515	0.68	15/20
Ditolylguanidine (SCHEMBL80339)	1.00	14/20
SCHEMBL27318	0.54	14/20
Guanabenz (SCHEMBL15390)	0.65	11/20
SCHEMBL45769	0.68	10/20
Memantine (SCHEMBL2688)	1.00	9/20
Memantine (SCHEMBL2689)	1.00	9/20
Radiprodil (SCHEMBL99256)	1.00	9/20
Memantine (SCHEMBL3053)	0.95	9/20
SCHEMBL77639	0.60	9/20
SCHEMBL100555	0.58	9/20
SCHEMBL42127	0.54	9/20
SCHEMBL77520	0.54	9/20
SCHEMBL79421	0.49	9/20
SCHEMBL78363	0.47	9/20
SCHEMBL87024	0.43	9/20
Levorphanol (SCHEMBL24335)	1.00	8/20
Racemorphan (SCHEMBL46201)	1.00	8/20
SCHEMBL10673	0.53	8/20
SCHEMBL79596	0.50	8/20

Clinical trials — most relevant to GRIN2B by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Treatment of Cognitive and Negative Symptoms in Schizophrenia With N-acetylcysteine	PHASE4	COMPLETED
PCA Ketamine-Morphine VS PCA Morphine as Post-Operative Analgesia in Colorectal Surgery.	PHASE4	COMPLETED
TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders	PHASE3	RECRUITING
Memantine for Refractory OCD Patients	PHASE3	UNKNOWN
A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial	PHASE2/PHASE3	NOT_YET_RECRUITING
A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease	PHASE3	COMPLETED
Prehospital Early Administration of Ketamine for Status Epilepticus in Epileptic Kids (PEAK-SEEK)	PHASE2/PHASE3	RECRUITING
Effect of Sarcosine on Symptomatology, Quality of Life, Oxidative Stress and Glutamatergic Parameters in Schizophrenia	PHASE2	COMPLETED
Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders	PHASE2	COMPLETED
Synaptic Mechanisms of Intermittent Theta Burst Stimulation for Major Depressive Disorder	PHASE1/PHASE2	NOT_YET_RECRUITING
Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder	PHASE2	COMPLETED
High Dose D-Serine as Adjuvant Treatment for Recent Onset Schizophrenia	PHASE2	UNKNOWN
Effects of Direct Transcranial Current Stimulation on Central Neural Pain Processing in Fibromyalgia	PHASE1/PHASE2	COMPLETED
Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression	PHASE1	RECRUITING
Antidepressant Effects of NR2B in Major Depression	PHASE1	COMPLETED
Biomarkers of Fast Acting Therapies in Major Depression	PHASE1	COMPLETED
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine	EARLY_PHASE1	COMPLETED
D-aspartate and Therapeutic Exercise	EARLY_PHASE1	UNKNOWN
Tolerability and Efficacy of L-Serine in Patients With GRIN-related Encephalopathy	nan	UNKNOWN
The Impact of Pharmacological and Electric Modulation of NMDA Pathway on the Cognitive Flexibility and Volitional Movement Preparation in Patients With Parkinson's Disease	nan	COMPLETED
An Assessment of Cognitive Function in Irritable Bowel Syndrome	nan	UNKNOWN
Acamprosate: Genes Associated With Response	nan	COMPLETED
Development of a Novel Glutamate Receptor Ligand for PET Scans in Neuropsychiatric Systemic Lupus Erythematosus	nan	COMPLETED
PET Imaging of Brain mGluR1 Receptors Using [18F]FIMX	nan	COMPLETED
Mechanisms of Human Plasticity in the Human System	nan	COMPLETED
Effect of Dexmedetomidine Combined With Low-dose Nalmefene on Preventing Remifentanil-induced Postoperative Hyperalgesia	nan	COMPLETED
The Neuroprotective Effect of Dexmedetomidine Preserving Brain Functional Connectivity in Elderly Patients	nan	COMPLETED
Effect of Butorphanol Combined With Flurbiprofen Axetil on Preventing Hyperalgesia Induced by Remifentanil in Patients	nan	COMPLETED
7 Tesla MRI Brain Imaging to Decipher Filgotinib's Mode of Analgesic Action in Rheumatoid Arthritis	nan	RECRUITING
L-arginine add-on Therapy in Patients With Schizophrenia	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a GRIN2B binder may also engage these)

Protein	Name	Similarity
Q00960	—	1.000	Q00960 →
Q5R1P3	—	1.000	Q5R1P3 →
Q01097	—	1.000	Q01097 →
A7XY94	—	1.000	A7XY94 →
P35436	—	0.997	P35436 →
B7ZSK1	—	0.997	B7ZSK1 →
Q5IS45	—	0.995	Q5IS45 →
GRIN2A	Glutamate receptor ionotropic, NMDA 2A	0.994	landscape →
Q00959	—	0.991	Q00959 →
B3LZ39	—	0.978	B3LZ39 →
B4MU83	—	0.977	B4MU83 →
Q24418	—	0.977	Q24418 →
B4LZB5	—	0.976	B4LZB5 →
B4KD90	—	0.976	B4KD90 →
B4JHV0	—	0.975	B4JHV0 →
B4QWW7	—	0.975	B4QWW7 →
B4I414	—	0.974	B4I414 →
B4PVB0	—	0.974	B4PVB0 →
B4GF83	—	0.973	B4GF83 →
Q296F7	—	0.972	Q296F7 →
B3P2E5	—	0.971	B3P2E5 →
A0A1S4F362	—	0.965	A0A1S4F362 →
Q9Z2W9	—	0.961	Q9Z2W9 →
P19492	—	0.961	P19492 →
TRPM8	Transient receptor potential cation channel subfamily M member 8	0.961	landscape →
GRIA3	Glutamate receptor 3	0.960	landscape →
Q8R455	—	0.959	Q8R455 →
P58421	—	0.959	P58421 →
Q9W365	—	0.959	Q9W365 →
Q9DEB5	—	0.959	Q9DEB5 →